The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Mechanisms of protein-folding diseases at a glance
Open accessAbstract
For a protein to function appropriately, it must first achieve its proper conformation and location within the crowded environment inside the cell. Multiple chaperone systems are required to fold proteins correctly. In addition, degradation pathways participate by destroying improperly folded proteins. The intricacy of this multisystem process provides many opportunities for error. Furthermore, mutations cause misfolded, nonfunctional forms of proteins to accumulate. As a result, many pathological conditions are fundamentally rooted in the protein-folding problem that all cells must solve to maintain their function and integrity. Here, to illustrate the breadth of this phenomenon, we describe five examples of protein-misfolding events that can lead to disease: improper degradation, mislocalization, dominant-negative mutations, structural alterations that establish novel toxic functions, and amyloid accumulation. In each case, we will highlight current therapeutic options for battling such diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Protein Misfolding, Functional Amyloid, and Human Disease
Chiti, F., & Dobson, C. M. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.101304.123901 · Cited by 6,423
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064 · cited 1×
“Indeed, antibodies have recently been developed that generically recognize both amyloid fibrils and toxic oligomers, and it has been shown that an oligomerspecific antibody blocks the toxicity of multiple types of oligomers in vitro (Kayed et al., 2003; Glabe, 2004).”
BackgroundMolecular chaperones in protein folding and proteostasis
Hartl, F. U., Bracher, A., & Hayer-Hartl, M. (2011) · Nature · doi:10.1038/nature10317 · Cited by 3,381
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 4×
“These compounds prevent MDM2 from interacting with and promoting degradation of WT p53, increasing the probability of forming WT, functional tetramers (Vassilev et al., 2004).”
BackgroundInfluentialLuk, K. C., Kehm, V., Carroll, J., Zhang, B., O’Brien, P., Trojanowski, J. Q., & Lee, V. M.-Y. (2012) · Science · doi:10.1126/science.1227157 · Cited by 2,563
The Protein-Folding Problem, 50 Years On
Dill, K. A., & MacCallum, J. L. (2012) · Science · doi:10.1126/science.1219021 · Cited by 1,699
Caughey, B., & Lansbury, P. T. (2003) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.010302.081142 · Cited by 1,650 · cited 2×
“These range from neurodegenerative disorders (including AD, Parkinson’s disease and Huntington’s disease) to amyloidoses (such as familial amyloid polyneuropathy and primary systemic amyloidosis) (Caughey and Lansbury, 2003; Chiti and Dobson, 2006).”
BackgroundTargeting the dynamic HSP90 complex in cancer
Trepel, J., Mollapour, M., Giaccone, G., & Neckers, L. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2887 · Cited by 1,514
Whitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., & Neckers, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8324 · Cited by 1,444
Cited by
Neurodegenerative disease: models, mechanisms, and a new hope
Gitler, A. D., Dhillon, P., & Shorter, J. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.030205 · Cited by 739
Mahul-Mellier, A.-L., Burtscher, J., Maharjan, N., Weerens, L., Croisier, M., Kuttler, F., Leleu, M., Knott, G. W., & Lashuel, H. A. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1913904117 · Cited by 710
Protein Quality Control by Molecular Chaperones in Neurodegeneration
Ciechanover, A., & Kwon, Y. T. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00185 · Cited by 346
The therapeutic effects of 4-phenylbutyric acid in maintaining proteostasis
Kolb, P. S., Ayaub, E. A., Zhou, W., Yum, V., Dickhout, J. G., & Ask, K. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.01.015 · Cited by 273
ER stress and UPR in Alzheimer’s disease: mechanisms, pathogenesis, treatments
Ajoolabady, A., Lindholm, D., Ren, J., & Pratico, D. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05153-5 · Cited by 261
Second-Generation Pharmacological Chaperones: Beyond Inhibitors
Tran, M. L., Génisson, Y., Ballereau, S., & Dehoux, C. (2020) · Molecules · doi:10.3390/molecules25143145 · Cited by 63
Documentation of an Imperative To Improve Methods for Predicting Membrane Protein Stability
Kroncke, B. M., Duran, A. M., Mendenhall, J. L., Meiler, J., Blume, J. D., & Sanders, C. R. (2016) · Biochemistry · doi:10.1021/acs.biochem.6b00537 · Cited by 50
Aggregation and disaggregation features of the human proteome
Määttä, T. A., Rettel, M., Sridharan, S., Helm, D., Kurzawa, N., Stein, F., & Savitski, M. M. (2020) · Molecular Systems Biology · doi:10.15252/msb.20209500 · Cited by 34
Impact of Heat Shock Proteins in Neurodegeneration: Possible Therapeutical Targets
Beretta, G., & Shala, A. L. (2022) · Annals of Neurosciences · doi:10.1177/09727531211070528 · Cited by 32
Bacci, A., Runfola, M., Sestito, S., & Rapposelli, S. (2021) · Antioxidants · doi:10.3390/antiox10030367 · Cited by 23
Sequestration of TDP-43 216-414 Aggregates by Cytoplasmic Expression of the proSAAS Chaperone
Peinado, J. R., Chaplot, K., Jarvela, T. S., Barbieri, E. M., Shorter, J., & Lindberg, I. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00156 · Cited by 16
Pathfinder: Protein folding pathway prediction based on conformational sampling
Huang, Z., Cui, X., Xia, Y., Zhao, K., & Zhang, G. (2023) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1011438 · Cited by 13
Metadata
- Authors
- Valastyan, J. S., & Lindquist, S.
- Venue
- Disease Models & Mechanisms
- Publisher
- The Company of Biologists
- Published
- 2014-01-01
- Volume
- 7
- Issue
- 1
- Pages
- 9-14
- ISSN
- 1754-8403 (ISSN-L)
- 1754-8411
- OpenAlex
- W2156098042
- Cited by
- 307
- References
- 69
- FWCI
- 12.41
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.